Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Loyola University
Jonsson Comprehensive Cancer Center
University of Pittsburgh
Fred Hutchinson Cancer Center
Mesoblast, Ltd.